Repository logo
 
Publication

Plasmatic microRNAs and treatment outcomes of patients with metastatic castration-resistant prostate cancer: a hospital-based cohort study and in silico analysis

2023-05-22Journal article Restricted access
Simple item page
dc.contributor.authorSilva, Jani
dc.contributor.authorTavares, Valéria
dc.contributor.authorAfonso, Ana
dc.contributor.authorGarcia, Juliana
dc.contributor.authorCerqueira, Fátima
dc.contributor.authorMedeiros, Rui
dc.date.accessioned2025-11-25T13:56:09Z
dc.date.available2025-11-25T13:56:09Z
dc.date.issued2023-05-22
dc.description.abstractProstate cancer (PCa) is one of the most common malignancies among men worldwide. Inevitably, all advanced PCa patients develop metastatic castration-resistant prostate cancer (mCRPC), an aggressive phase of the disease. Treating mCRPC is challenging, and prognostic tools are needed for disease management. MicroRNA (miRNA) deregulation has been reported in PCa, constituting potential non-invasive prognostic biomarkers. As such, this study aimed to evaluate the prognostic potential of nine miRNAs in the liquid biopsies (plasma) of mCRPC patients treated with second-generation androgen receptor axis-targeted (ARAT) agents, abiraterone acetate (AbA) and enzalutamide (ENZ). Low expression levels of miR-16-5p and miR-145-5p in mCRPC patients treated with AbA were significantly associated with lower progression-free survival (PFS). The two miRNAs were the only predictors of the risk of disease progression in AbA-stratified analyses. Low miR-20a-5p levels in mCRPC patients with Gleason scores of <8 were associated with worse overall survival (OS). The transcript seems to predict the risk of death regardless of the ARAT agent. According to the in silico analyses, miR-16-5p, miR-145-5p, and miR-20a-5p seem to be implicated in several processes, namely, cell cycle, proliferation, migration, survival, metabolism, and angiogenesis, suggesting an epigenetic mechanism related to treatment outcome. These miRNAs may represent attractive prognostic tools to be used in mCRPC management, as well as a step further in the identification of new potential therapeutic targets, to use in combination with ARAT for an improved treatment outcome. Despite the promising results, real-world validation is necessary.
dc.identifier.citationSilva, J.; Tavares, V.; Afonso, A.; Garcia, J.; Cerqueira, F.; Medeiros, R. Plasmatic microRNAs and treatment outcomes of patients with metastatic castration-resistant prostate cancer: a hospital-based cohort study and in silico analysis. Int. J. Mol. Sci. 2023, 24, 9101. https://doi.org/10.3390/ ijms24109101
dc.identifier.doihttps://doi.org/10.3390/ijms24109101
dc.identifier.eissn1422-0067
dc.identifier.other37240449
dc.identifier.urihttp://hdl.handle.net/10284/14774
dc.language.isoeng
dc.peerreviewedyes
dc.publisherMDPI
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectProstatic neoplasms
dc.subjectAbiraterone acetate
dc.subjectEnzalutamide
dc.subjectPrognosis
dc.subjectBiomarkers
dc.subjectLiquid biopsy
dc.subjectHsa-miR-16-5p
dc.subjectHsa-miR-145-5p
dc.subjectHsa-miR-20a-5p
dc.titlePlasmatic microRNAs and treatment outcomes of patients with metastatic castration-resistant prostate cancer: a hospital-based cohort study and in silico analysiseng
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue10
oaire.citation.titleInternational Journal o f Molecular Sciences
oaire.citation.volume24
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85
person.familyNameSilva
person.familyNameTavares
person.familyNameCerqueira
person.familyNameMedeiros
person.givenNameJani
person.givenNameValéria
person.givenNameFátima
person.givenNameRui
person.identifier812695
person.identifier37604
person.identifier.ciencia-idCF14-52ED-5DA0
person.identifier.ciencia-idC51F-5DBE-9C51
person.identifier.orcid0000-0001-5868-4669
person.identifier.orcid0000-0003-3680-7757
person.identifier.orcid0000-0003-4513-4654
person.identifier.orcid0000-0003-3010-8373
person.identifier.ridM-7557-2013
person.identifier.ridC-7938-2009
person.identifier.scopus-author-id6603346911
person.identifier.scopus-author-id7006241641
relation.isAuthorOfPublication6b9e0ed3-2d16-40f5-820d-2f62717b7fd2
relation.isAuthorOfPublication944a41f5-0d57-4860-b429-bb73d0109e9c
relation.isAuthorOfPublication2705e35c-97f6-4de2-bbf1-d680342760e9
relation.isAuthorOfPublication5ffb7965-d9af-4ba1-a81b-b0aed28de206
relation.isAuthorOfPublication.latestForDiscovery6b9e0ed3-2d16-40f5-820d-2f62717b7fd2

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Plasmatic microRNAs and treatment outcomes of patients with metastatic castration-resistant prostate cancer
Size:
4.49 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.03 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

FCS - Artigos em Revistas Científicas Internacionais com Arbitragem Científica